Rahul Banerjee, Assistant Professor at the Fred Hutchinson Cancer Center and at the University of Washington, shared a post on LinkedIn about a paper by Sueh-li Lim et al. published in Wiley Online Library:
” Important British Journal of Haematology work by Lim Hang Quach et al re: functional high risk MMsm.
OS similarly poor for FHRMM, regardless of frontline IMiD versus not. In these pts, no OS benefit for 2L dara. Better options needed for FHRMM: will CAR-T or bsAbs some day become normal?
Similar to great analysis by Utkarsh Goel, Danai Dima of CIBMTR trials that I happened to present on their behalf at IMS25 in Toronto.
Don’t underestimate FHRMM… disease biology is sending you a message regardless of what induction regimen was!
Link to British Journal of Haematology article.”
Title: No benefit from daratumumab, bortezomib and dexamethasone (D-Vd) in real-world patients with functional high-risk multiple myeloma: A report from the Myeloma and Related Diseases Registry
Authors: Sueh-li Lim, Cameron Wellard, Rajeev Rajagopal, Simon J. Harrison, Amit Khot, Hang Quach, Phoebe J. Ho, Elizabeth Moore, Erica Wood, Andrew Spencer
Read The Full Article in Wiley Online Library.
More posts from Rahul Banerjee.